Derived From Fungi, E.g., Yeasts, Mushroom, Etc. Patents (Class 530/371)
-
Patent number: 5374714Abstract: A method of obtaining a novel polypeptide from a crude extraction product of polysaccharide peptide Coriolus versicolor comprising: a) boiling a water soluble powder of polysaccharide peptide Coriolus versicolor; b) centrifuging a boiled product from step a); c) filtering a centrifuged product from step b); d) purifying a solution from step c) by gel filtration chromatography; e) subjecting the purified material from step d) to HPLC using a reversed-phase at ambient temperature, wherein a solvent composition is at an acidic Ph and further includes KCl solvent, and wherein an elution system consists of a linear gradient of about 80% methanol applied at a rate of from between 0-40 minutes to obtain chromatographic peaks; f) analyzing the chromatographic peaks by monitoring for absorbance at about 230 nm, 1.0 AUFS for protein analysis and about 620 nm, 0.Type: GrantFiled: November 30, 1992Date of Patent: December 20, 1994Inventors: Mable M. P. Yang, George Chen
-
Patent number: 5356874Abstract: Disclosed herein is purified isolated angiogenic factor, isolated from Live Yeast Cell Derivitive. Also disclosed herein are methods to treat mammals suffering from wounds or burns comprising administering the angiogenic factor and pharmaceutical formulations for use in the methods.Type: GrantFiled: February 22, 1993Date of Patent: October 18, 1994Assignee: State of Oregon acting by and through the Oregon State Board of Higher Education on behalf of the Oregon Health Sciences UniversityInventor: J. Peter Bentley
-
Patent number: 5334704Abstract: Disclosed herein is a novel glycoprotein derived from Ganoderma mycelia. The glycoprotein is free of human hemagglutination ability, and has immunosuppressive activities and a molecular weight of 16,000-18,000 as measured by SDS gel electrophoresis or 12,000-16,000 as measured by tricin-SDS gel electrophoresis. The glycoprotein is produced by culturing Ganoderma mycelia, extracting the resultant Ganoderma mycelia with an aqueous solvent, and then purifying the resultant extract. An immunosuppressive agent containing an effective amount of the glycoprotein is also disclosed.Type: GrantFiled: April 28, 1988Date of Patent: August 2, 1994Assignee: Meiji Milk Products Co., Ltd.Inventors: Hajime Tsunoo, Kousuke Kino, Akio Yamashita
-
Patent number: 5302699Abstract: Disclosed is an antitumorigenic protein derived from fruit bodies of matsutake mushrooms (Tricholoma matsutake). Also disclosed is a method of preparing the antitumorigenic protein comprising extracting fruit bodies of matsutake mushrooms with water followed by subjecting the resulting extract to purification composed of combination of the following three purifying steps in any desired order:(1) a step of purifying the protein by molecular sieve chromatography in a gel permeation column;(2) a step of bringing the extract in contact with an anion exchange resin so that the protein is adsorbed to the resin followed by eluting the protein from the column of the resin with an eluent; and(3) a step of bringing the extract in contact with a hydrophobic chromatographic resin so that the protein is adsorbed to the resin followed by eluting the protein from the column of the resin with an eluent.Type: GrantFiled: January 22, 1993Date of Patent: April 12, 1994Assignees: Director of National Food Research Institute, Ministry of Agriculture, Forestry and Fisheries, Momoya Co., Ltd.Inventors: Yukio Kawamura, Akihiro Morita, Makoto Tomatsu, Masaru Ishikawa
-
Patent number: 5288639Abstract: A polypeptide sequence from Candida albicans is described which has significant sequence homology with known stress proteins from other organisms, particularly the heat shock protein hsp 90 of Sacchromyces cerevisiae. Corresponding DNA sequences are also described, together with antibodies raised against fragments of the sequence. The polypeptide and DNA sequences and antibodies provide separate means for the diagnosis and/or treatment of fungal, particularly Candida, infections.Type: GrantFiled: March 14, 1991Date of Patent: February 22, 1994Assignee: The Victoria University of ManchesterInventors: James P. Burnie, Ruth C. Matthews
-
Patent number: 5284934Abstract: The present invention provides a process for preparing a carbohydrate-binding lectin derivative for use as immune modulators or immunoconjugates. The polymer-lectin conjugate produced in accordance with the process is polyethylene glycol Ricinus communis agglutinin I (PEG-RCAI). The lectin is coupled to the polymer by activating the polymer with a coupling agent such as 1,1-carbonyldiimidazole. The polymer-lectin conjugate is biologically active, biocompatible and is expected to be substantially non-immunogenic.Type: GrantFiled: September 4, 1992Date of Patent: February 8, 1994Assignee: Health Research Inc.Inventor: Howard J. Allen, Jr.
-
Patent number: 5281577Abstract: An inhibitor of the proliferation of herpesviruses and of the recurrence of affections caused by their latent infection, which is an active material obtained by fractional purification of the aqueous extract from cultured Lentinus edodes mycelia.Type: GrantFiled: October 15, 1992Date of Patent: January 25, 1994Assignees: JCR Pharmaceuticals Co., Ltd., Noda Shokukin Kogyo Co., Ltd.Inventors: Junichi Koga, Yasuhiro Ohashi, Hajime Hiratani
-
Patent number: 5250664Abstract: Process for tanning a protein substance, in particular one of vegetable oin, such as oil seed proteins, characterized in that it includes treating the said protein substance with a dithiocarbamate type compound, partially degraded by a strong acid.Type: GrantFiled: October 16, 1991Date of Patent: October 5, 1993Assignee: Societe Nationale de Commercialisation des Oleagineux du SenegalInventors: Jacques P. Fromont, Claude Portilla
-
Patent number: 5238925Abstract: Disclosed herein is purified isolated angiogenic factor, isolated from Live Yeast Cell Derivative. Also disclosed herein are methods to treat mammals suffering from wounds or burns comprising administering the angiogenic factor and pharmaceutical formulations for use in the methods.Type: GrantFiled: May 9, 1990Date of Patent: August 24, 1993Assignee: The State of Oregon Acting by and through The State Board of Higher Education on Behalf of the Oregon Health Sciences UniversityInventor: J. Peter Bentley
-
Patent number: 5215898Abstract: A novel cytotoxic protein is described possessing antifungal activity and which may be used for the treatment of fungal infections, or the prevention or control of fungal growth, as well as being potentially valuable as a biopesticide such as an insecticide, nematicide, or herbicide. The protein is produced by culture of Pichia inositovora strain NRRL Y-18709, and may be subsequently recovered from the culture medium and purified.Type: GrantFiled: July 22, 1991Date of Patent: June 1, 1993Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Paul L. Bolen, G. Thomas Hayman
-
Patent number: 5173419Abstract: Two chitinases from Trichoderma harzianum P1 (ATCC 74058) show chitin-containing-fungus- and insect-inhibiting activity. The first is an endochitinase having a molecular weight of 36 kDa and an isoelectric point of 5.3.+-.0.2. The second is an exochitinase having a molecular weight of 36 kDa an an isoelectric point of 4.4.+-.0.2. The chitinases can be applied in contact with chitin-containing fungus or insect as an inhibitor thereof. The chitinases can be applied to plants or to soil around plants which need production from a chitinase-containing pest. The chitinases can also be used to isolate genes coding for them which can be inserted into a genome of a plant needing protection from a chitinase-containing pest or into the genome of a microorganism to provide transgenic microorganism useful to produce enzyme or as a biocontrol agent.Type: GrantFiled: June 17, 1991Date of Patent: December 22, 1992Assignee: Cornell Research Foundation, Inc.Inventors: Gary E. Harman, Roxanne M. Broadway, Arne Tronsmo, Matteo Lorito
-
Patent number: 5112607Abstract: A method of potentiating immunotoxin action in an immunotoxin/target-cell stem in which Brefeldin A is utilized as an immunopotentiator. The Brefeldin A enhances the immunotoxin pathway while blocking or inhibiting the nonspecific pathway, thus being particularly useful in conjunction with immunotoxins made from holotoxins. The Brefeldin A is effective in small, nontoxic concentrations and therefore may be utilized with either in vivo or in vitro systems.Type: GrantFiled: June 5, 1991Date of Patent: May 12, 1992Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Thomas H. Hudson, Michael A. King
-
Patent number: 5102989Abstract: Recombinant hepatitis B virus surface proteins produced in recombinant host cells are rapidly and efficiently purified from either cell extracts in a high pH buffer, or from heated whole cells at neutral pH. The host cell extracts or whole cells are heat treated, cooled and in the case of high pH extract, the pH is reduced. The surface proteins are then absorbed onto wide pore silica followed by elution and concentration. This method eliminates the requisite introduction of protease inhibitors, stabilizes the surface protein and improves product yield.Type: GrantFiled: March 15, 1991Date of Patent: April 7, 1992Assignee: Merck & Co., Inc.Inventors: Robert D. Sitrin, Dennis J. Kubek
-
Patent number: 5093118Abstract: A cell wall protein of the fungus B. dermatitidis is isolated and purified. The protein is readily recognized by serum antibodies from animals having blastomycosis. The protein antigen can be labelled to provide an assay for detection of the disease, it can be used to stimulate specific lymphocyte response and thereby provide another assay for detection of the disease, it can be used to produce an immune response to B. dermatitidis, or it can be used to create antibodies to the protein.Type: GrantFiled: September 14, 1989Date of Patent: March 3, 1992Assignee: Wisconsin Alumni Research FoundationInventors: Bruce S. Klein, Jeffrey M. Jones
-
Patent number: 5011915Abstract: Methods of purifying recombinant surface antigen of hepatitis B virus are disclosed. In one protocol, purification is achieved by selective extraction of the antigen from yeast membranes, followed by solubilization with urea and dithiothreitol.Type: GrantFiled: October 26, 1987Date of Patent: April 30, 1991Assignee: Merck & Co., Inc.Inventor: Shigeko Yamazaki
-
Patent number: 4911912Abstract: Glycoprotein (GPIR) having the ribosome-inhibiting activity of the native GPIR and having a prolonged-action in vivo which is obtained by oxidation of its osidic units by the action of periodate ions, and simultaneous reduction with cyanoborohydride ions. Said modified glycoprotein may be coupled to an antibody or a fragment thereof in order to form an immunotoxin having a prolonged-action in vivo.Type: GrantFiled: December 15, 1986Date of Patent: March 27, 1990Assignee: SanofiInventors: Pierre Casellas, Bernard Bourrie, Xavier Canat
-
Patent number: 4911911Abstract: Glycoprotein (GPIR) the ribosome-inhibiting activity of the native GPIR and having a prolongedaction in vivo which is obtained by oxidation of its osidic units by the action of periodate ions, and simultaneous blocking of the oxidation product by formation of a Schiff's base with a suitable primary amine. Said modified glycoprotein may be coupled to an antibody or a fragment thereof in order to form an immunotoxin.Type: GrantFiled: December 15, 1986Date of Patent: March 27, 1990Assignee: SanofiInventors: Pierre Casellas, Bernard Bourrie, Xavier Canat
-
Patent number: 4909941Abstract: There is described a mobile phase for use in the purification of proteins using reversed phase HPLC on a preparative scale. The mobile phase is an aqueous solution containing 0.005 to 1M of a physiologicially acceptable acid of the general formula YCOOH where Y is a polar electron withdrawing group capable of hydrogen bonding silanol groups. The solution also contains up to 95% by volume of a physilogically acceptable organic solvent. A preparative method of purifying proteins such as HSA or BSA and recombinant deoxyribonucleic proteins using reversed phased PHLC is also described.Type: GrantFiled: December 8, 1988Date of Patent: March 20, 1990Inventors: Dick J. Poll, David R. K. Harding, William S. Hancock
-
Patent number: 4857317Abstract: The process is applicable to the supernatant of engineered yeast cells disrupted in the presence of a non-ionic detergent; it comprises the precipitation of contaminants by polyethylene glycol and the treatment of this latter supernatant with either a bivalent metal cation or, after eventual ultrafiltration, with ammonium sulfate.Type: GrantFiled: April 27, 1987Date of Patent: August 15, 1989Assignee: SmithKline BiologicalsInventors: Frans V. Wijnendaele, Daniel Gilles, Guy Simonet
-
Patent number: 4806465Abstract: Two novel hybridoma cell lines, ATCC #HB-8397 and ATCC #HB-8398 produce monoclonal antibody monospecific to a single determinant shared by a set of three closely related cytoplasmic antigens of Candida albicans. The antigens have molecular weights of 120-135 Kd, 48-52 Kd, and 35-38 Kd. The hybridomas are formed by fusing splenocytes from immunized BALB/c mice with SP2/O-Ag 14 myeloma cells. Monoclonal and monospecific, polyclonal antibodies to these cytoplasmic antigens find application in the immunodiagnosis of Candida infections.A procedure is provided for preparing partially purified cytoplasmic antigen of pathogenic Candida species for administration to splenocyte-donating mice. Also provided is a method for the biochemical purification of cytoplasmic antigen of a pathogenic Candida species used for the preparation of monoclonal and monospecific, polyclonal antisera thereto.Type: GrantFiled: March 30, 1987Date of Patent: February 21, 1989Assignee: Temple University of the Commonwealth System of Higher EducationInventors: Helen R. Buckley, Michael T. Largen, Nancy A. Strockbine
-
Patent number: 4789658Abstract: An immunopropylactic and immunotherapeutic agent comprising human interleukin 2 of human cellular origin is disclosed along with a method of producing the agent.Type: GrantFiled: June 9, 1986Date of Patent: December 6, 1988Assignee: Ajinomoto Company, IncorporatedInventors: Ryota Yoshimoto, Nobukazu Kashima, Junji Hamuro, Koji Mitsugi
-
Patent number: 4746647Abstract: A method of purifying a contaminated product (protein/peptide) produced by rDNA technique, from hydrophobic contaminants which are charged and originate from the microbial cloning host employed, and the product thus purified are disclosed. The contaminated product is subjected to electroseparation, such as electrodialysis, to remove the contaminants. A charge-providing pretreatment is resorted to when the contaminants themselves are not charged enough to enable them to be directly separated upon electroseparation. In addition, a method of checking the purity of a product (protein/peptide) produced by rDNA technique is disclosed. Moreover, a method of checking the efficiency of the purification process used for purifying a product is disclosed.Type: GrantFiled: March 14, 1986Date of Patent: May 24, 1988Inventor: Stefan Svenson
-
Patent number: 4742158Abstract: Recombinant pre-S-HBsAg is purified by a rapid and efficient two step chromatographic process. Yeast cells expressing recobinant pre-S-HBsAg are disrupted, the cell contents are clarified and separated by polymerized human serum albumin affinity chromatography. The pre-S-HBsAg is further purified by hydrophobic interaction chromatography using butyl agarose. This process results in pre-S-HBsAg that is greater than 90% pure.Type: GrantFiled: April 14, 1987Date of Patent: May 3, 1988Assignee: Merck & Co., Inc.Inventors: E. Dale Lehman, Ted F. Schaefer, William J. McAleer
-
Patent number: 4707542Abstract: The surface antigen protein of human Hepatitis B virus is synthesized in Saccharomyces cerevisiae as a 23,000-26,000 dalton polypeptide, essentially free of intermolecular disulfide bonds. This antigen is a poor immunogen in animals and man. No prior precedent or method exists for efficiently converting the non-disulfide bonded antigen to a fully intermolecular disulfide bonded particle. We describe the first example of such a conversion in vitro and show that the act of this conversion enhances the immunogenicity of the antigen about 10-fold. The in vitro conversion makes practical the production of hepatitis B surface antigen from microorganisms using recombinant DNA methods.Type: GrantFiled: August 1, 1984Date of Patent: November 17, 1987Assignee: Merck & Co., Inc.Inventors: Arthur Friedman, E. Dale Lehman, William J. McAleer, Ted F. Schaefer, Edward M. Scolnick, D. Eugene Wampler
-
Patent number: 4701442Abstract: A process for preparing nucleoproteic material which comprises immersing organic material into a suitable solvent for a sufficient time to extract nucleoproteins from said material, adding a sufficient amount of an acid to form a precipitate of nucleoproteic material, and recovering said nucleoproteic material precipitate. A composition of nucleoproteic material produced according to this process. A method for alleviating symptoms of neoplastic diseases which comprises sterilizing the composition of nucleoproteic material, preparing a formulation comprising an effective amount of said sterilized composition, and administering said formulation to a patient having symptoms of a neoplastic disease.Type: GrantFiled: June 13, 1985Date of Patent: October 20, 1987Assignee: Elena AvramInventor: Emanuel Revici
-
Patent number: 4683294Abstract: The process is applicable to the supernatant of engineered yeast cells disrupted in the presence of a non-ionic detergent: it comprises the precipitation of contaminants by polyethylene glycol and the treatment cation or, after eventual ultrafiltration, with ammonium sulfate.Type: GrantFiled: April 3, 1985Date of Patent: July 28, 1987Assignee: Smith Kline RIT, S.A.Inventors: Frans Van Wijnendaele, Daniel Gilles, Guy Simonet
-
Patent number: 4683293Abstract: Method for the selective extraction of desired lipophilic proteins from transformed cells of the genus Pichia by cell lysis in the presence of chaotrophic salts is disclosed. The total protein extracted under the invention cell lysis conditions is reduced while the recovery of desired lipophilic proteins remains relatively constant, thereby producing a cell extract with enhanced concentration of the desired lipophilic protein relative to a control cell extract.Type: GrantFiled: October 20, 1986Date of Patent: July 28, 1987Assignee: Phillips Petroleum CompanyInventor: William S. Craig
-
Patent number: 4665158Abstract: Dehydrated protein materials are treated with gaseous HCl without temperature control, the reaction temperature being susceptible to reach, momentarily, 150.degree. C. Then the material thus treated is degassed and, after drying, a non hygroscopic powder usable in the food industry or in the pharmaceutical industry is obtained.Type: GrantFiled: May 30, 1985Date of Patent: May 12, 1987Assignee: Battelle Memorial InstituteInventors: Jean-Michel Armanet, Claude Giddey, Jean-Pierre Sachetto
-
Patent number: 4649192Abstract: The supernatant of engineered yeast cells having produced hepatitis B surface antigaen and disrupted in the presence of a polysorbate non-ionic detergent is clarified by addition of urea and adsorbed on colloidal silica from which the purified antigen is desorbed with a low ionic strength buffer supplemented with urea and a polysorbate non-ionic detergent.Type: GrantFiled: May 30, 1985Date of Patent: March 10, 1987Assignee: Smith Kline-RITInventors: Frans Van Wijnendaele, Guy Simonet